Feedback
Contactin-Associated Protein-2 Antibody, IgG with Reflex to Titer, CSF
3001986
Ordering Recommendation

Aid in diagnosis of contactin associated protein 2 (CASPR2) antibody disorders associated with acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Use to manage antibody-positive (CASPR2) individual following immunotherapy and/or plasmapheresis. Serum is the preferred specimen; see Contactin-Associated Protein-2 Antibody, IgG with Reflex to Titer, Serum (2009452).

Mnemonic
CASPR2GCSF
Methodology
Semi-Quantitative Indirect Fluorescent Antibody
Performed
Wed
Reported
1-8 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
CSF. 
Specimen Preparation
Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.15 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Contaminated, hemolyzed, or severely lipemic specimens. 
Remarks
 
Stability
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month 
Reference Interval
Less than 1:1
Interpretive Data
Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Tumors such as thymoma, small cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes contactin-associated protein-2 (CASPR2) transfected cell lines for the detection and semi-quantification of the CASPR2 IgG antibody.

Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
If CASPR2 antibody IgG is positive, then CASPR2 antibody IgG titer will be added. Additional charges apply.
Hotline History
View Hotline History
CPT Code(s)
Components
Component Test Code*Component Chart NameLOINC
3001987CASPR2 Ab IgG Screen by IFA, CSF90820-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases